Impact of fecal microbiota transplantation with capsules on the prevention of metabolic syndrome among patients with obesity
Author(s)
Type
Journal Article
Abstract
Background
Fecal microbiota transplantation (FMT) has been studied for the treatment of metabolic syndrome with varying success. However, the possibility of utilizing FMT to prevent metabolic syndrome is to date unknown.
Methods
Secondary analysis of a previously published double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients was conducted. Post-prandial glucose and insulin levels were measured (NCT02741518).
Results
A total of 22 patients were enrolled, 11 in each arm. There were no baseline differences in the area under the curve (AUC) of glucose or insulin in the FMT group compared to placebo. There was a significant change in glucose AUC at week 12 compared to baseline, and in the insulin AUC at week 6 compared to baseline in the FMT group vs. placebo (change in glucose AUC (mg/dl × 60 min): 579 vs 1978, p = 0.03) (change in insulin AUC (μU/ml × 60 min): 137 vs 2728, p = 0.01).
Conclusions
These data suggest that FMT may have a potential role in preventing the development of metabolic syndrome in patients with obesity.
Fecal microbiota transplantation (FMT) has been studied for the treatment of metabolic syndrome with varying success. However, the possibility of utilizing FMT to prevent metabolic syndrome is to date unknown.
Methods
Secondary analysis of a previously published double-blind, randomized, placebo-controlled pilot trial of FMT in obese metabolically healthy patients was conducted. Post-prandial glucose and insulin levels were measured (NCT02741518).
Results
A total of 22 patients were enrolled, 11 in each arm. There were no baseline differences in the area under the curve (AUC) of glucose or insulin in the FMT group compared to placebo. There was a significant change in glucose AUC at week 12 compared to baseline, and in the insulin AUC at week 6 compared to baseline in the FMT group vs. placebo (change in glucose AUC (mg/dl × 60 min): 579 vs 1978, p = 0.03) (change in insulin AUC (μU/ml × 60 min): 137 vs 2728, p = 0.01).
Conclusions
These data suggest that FMT may have a potential role in preventing the development of metabolic syndrome in patients with obesity.
Date Issued
2021-03
Date Acceptance
2020-11-25
Citation
Hormones, 2021, 20 (1), pp.209-211
ISSN
1109-3099
Publisher
Springer
Start Page
209
End Page
211
Journal / Book Title
Hormones
Volume
20
Issue
1
Copyright Statement
Copyright © 2021 Springer-Verlag. This version of the article has been accepted for publication, after peer review (when applicable) and is subject to Springer Nature’s AM terms of use, but is not the Version of Record and does not reflect post-acceptance improvements, or any corrections. The Version of Record is available online at: http://dx.doi.org/10.1007/s42000-020-00265-z
Identifier
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000606403100001&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=a2bf6146997ec60c407a63945d4e92bb
Subjects
Diabetes
Endocrinology & Metabolism
FMT
INSULIN SENSITIVITY
INTESTINAL MICROBIOTA
Life Sciences & Biomedicine
Metabolic syndrome
Obesity
Science & Technology
Publication Status
Published
Date Publish Online
2021-01-09